Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
Source: View publication →
In the phase 3 BRUIN CLL-322 trial, adding the noncovalent BTK inhibitor pirtobrutinib to standard fixed-duration venetoclax-rituximab significantly improved progression-free survival in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Key Findings
Study Design
Study Limitations
Clinical Significance
The BRUIN CLL-322 trial establishes pirtobrutinib plus venetoclax-rituximab as a highly effective, time-limited regimen for relapsed/refractory CLL, particularly given that 80% of the enrolled patients had prior exposure to covalent BTK inhibitors. By nearly halving the risk of progression or death compared to the existing standard of care, this triplet combination offers a robust new treatment strategy for a high-risk patient population, setting a new benchmark for targeted, fixed-duration combinations.
Historical Context
Following the landmark MURANO trial in 2018, the combination of venetoclax and rituximab became the standard fixed-duration regimen for patients with relapsed or refractory chronic lymphocytic leukemia. However, as frontline management shifted extensively toward continuous therapy with covalent BTK inhibitors (such as ibrutinib, acalabrutinib, and zanubrutinib), treating patients who progress after these agents has become a growing clinical challenge. Pirtobrutinib, a highly selective noncovalent BTK inhibitor, retains activity against CLL with acquired mutations that confer resistance to covalent inhibitors. The phase 3 BRUIN CLL-322 trial was designed to evaluate whether combining this noncovalent BTK inhibitor with the standard BCL2 inhibitor regimen could achieve deeper, synergistic responses and extend progression-free survival in a post-covalent BTK inhibitor era.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of pirtobrutinib compared to earlier generation inhibitors like ibrutinib, and why is its combination with venetoclax mechanistically synergistic in treating CLL?
Key Response
Pirtobrutinib is a highly selective, non-covalent (reversible) BTK inhibitor that binds independent of the C481 site, allowing it to overcome acquired resistance to covalent BTK inhibitors like ibrutinib. Venetoclax inhibits BCL-2, restoring apoptosis. BTK inhibition mobilizes CLL cells from lymph node niches into the peripheral blood, depriving them of microenvironmental survival signals and making them highly susceptible to venetoclax-induced apoptosis, providing a strong rationale for the combination.
When starting a patient on a venetoclax-based regimen, such as the triplet PVR used in this trial, what specific life-threatening complication must be anticipated and how is it managed during the initiation phase?
Key Response
Venetoclax is notorious for causing Tumor Lysis Syndrome (TLS) due to rapid, profound apoptosis of CLL cells. Management requires careful risk stratification based on tumor burden, prophylactic hydration, uric acid reducers like allopurinol or rasburicase, and a strict dose-escalation (ramp-up) schedule over 5 weeks, with frequent laboratory monitoring to prevent acute renal failure and lethal arrhythmias.
The BRUIN CLL-322 trial utilizes a fixed-duration approach. How does achieving undetectable minimal residual disease (uMRD) factor into the long-term success of time-limited combinations like PVR, and how might this influence sequencing options if a patient relapses?
Key Response
Deep remissions characterized by uMRD in blood and marrow are strongly correlated with prolonged progression-free survival in time-limited regimens. By using a non-covalent BTKi in a fixed-duration triplet, patients may achieve deeper remissions while preserving continuous therapy options or re-treatment upon relapse. This avoids the selective pressure of continuous BTK inhibition that typically leads to secondary resistance mutations.
While the BRUIN CLL-322 trial shows improved PFS with the PVR triplet, what considerations regarding toxicity, financial burden, and the exhaustion of multiple targeted therapy classes simultaneously should guide the decision to use this triplet over standard sequential therapy?
Key Response
While triplets drive deeper remissions, they combine the costs and overlapping toxicities (e.g., neutropenia, infection risk) of three agents. Furthermore, using a BTKi and a BCL2i simultaneously might leave fewer established options for subsequent relapses, making it critical to weigh the PFS benefit against overall survival, quality of life, and the importance of holding classes in reserve for future sequential use.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In an open-label trial design with progression-free survival as the primary endpoint, what specific forms of bias are introduced when evaluating a fixed-duration triplet versus a doublet, and how might independent blinded central review mitigate this?
Key Response
Open-label designs risk investigator bias in assessing disease progression and managing toxicities, especially when one arm involves a novel, highly anticipated agent. An Independent Review Committee (IRC) blinded to treatment assignment is crucial to objectively apply iwCLL criteria for progression, preventing premature declaration of events in the control arm or delayed declaration in the experimental arm.
Given that this trial focuses on previously treated CLL/SLL, how does the proportion of patients with prior covalent BTK inhibitor exposure impact the external validity of the results, and would the venetoclax-rituximab control arm be considered an appropriate standard of care for a heavily BTK-refractory subgroup?
Key Response
If the experimental PVR arm shows benefit primarily in BTKi-naive patients rather than BTKi-exposed, the magnitude of the drug's unique value is confounded by prior lines of therapy. A critical reviewer would demand subgroup analyses based on prior covalent BTKi exposure and C481 mutation status to validate whether the non-covalent BTKi adds true value or if the benefit is simply driven by adding another active agent in a less-refractory population.
Based on the BRUIN CLL-322 results, should pirtobrutinib plus venetoclax-rituximab be incorporated into the NCCN/ESMO guidelines as a preferred recommendation for relapsed/refractory CLL, and what specific prior treatment profiles would make this the most appropriate regimen?
Key Response
Current guidelines recommend VR (Category 1) for relapsed CLL, or pirtobrutinib monotherapy if prior covalent BTKi and BCL2i were used. The BRUIN CLL-322 data could elevate PVR to a Category 1 fixed-duration option. However, the committee must assess if the PFS benefit warrants the added toxicity over VR alone, potentially recommending it primarily for high-risk profiles or patients with documented progression on prior covalent BTK inhibitors who have not yet received a BCL2 inhibitor.
Clinical Landscape
Noteworthy Related Trials
MURANO Trial
Tested
Venetoclax plus rituximab
Population
Relapsed or refractory CLL
Comparator
Bendamustine plus rituximab
Endpoint
Progression-free survival (PFS)
GLOW Trial
Tested
Ibrutinib plus venetoclax
Population
Older or unfit patients with previously untreated CLL
Comparator
Chlorambucil plus obinutuzumab
Endpoint
Progression-free survival (PFS)
BRUIN Phase 1/2 Trial
Tested
Pirtobrutinib monotherapy
Population
Relapsed or refractory CLL/SLL previously treated with a BTK inhibitor
Comparator
None (single-arm)
Endpoint
Overall response rate (ORR)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis